Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven T Chen

Showing results (71-80 of 153) with videos related to

Pageof 16
Sort By:
Clinical and Experimental Dermatology|May 12, 2023
Low-grade cutaneous immune-related adverse events leading to immunotherapy discontinuationTed V Jacoby, Maria S Asdourian, Nishi Shah, et al.
JAMA Dermatology|April 14, 2021
Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced CancerLeah L Thompson, Jaewon Yoon, Nira A Krasnow, et al.
Journal of the American Academy of Dermatology|July 2, 2022
Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoidJordan T Said, Jordan Talia, Erin Wei, et al.
Journal of the American Academy of Dermatology|August 20, 2025
Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetesNatalie Braun, Claire Lin, Natalie Baker, et al.
International Journal of Dermatology|March 18, 2026
Effect of Diuretics on Cutaneous Squamous Cell Carcinoma: Clinical and Translational EvidenceKevin Sheng-Kai Ma, Stefano Sol, Fabiana Boncimino, et al.
Journal for Immunotherapy of Cancer|November 9, 2019
Budesonide treatment for microscopic colitis from immune checkpoint inhibitorsMichael S Hughes, Gabriel E Molina, Steven T Chen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 24, 2026
Effect of pre-existing atopic dermatitis on clinical outcomes of immune checkpoint therapyNatalie Braun, Bryan L Peacker, Natalie Baker, et al.
The British Journal of Dermatology|May 29, 2024
Sodium-glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseasesChin-Hsuan Shen, Yi-Sun Yang, Irene Tai-Lin Lee, et al.
International Journal of Dermatology|November 26, 2024
External validation study of Re-SCORTEN in patients with Stevens-Johnson syndrome and toxic epidermal necrolysisMike Westmeijer, Joseph Ebriani, Beatrix B Thompson, et al.
The American Journal of Dermatopathology|December 10, 2021
Cutaneous Findings of Sporadic, Adult-Onset Neuronal Intranuclear Inclusion DiseaseJakob M T Moran, Katharina Eikermann-Haerter, Otto Rapalino, et al.
Pageof 16

Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Clinical and Experimental Dermatology|May 12, 2023
Low-grade cutaneous immune-related adverse events leading to immunotherapy discontinuationTed V Jacoby, Maria S Asdourian, Nishi Shah, et al.
JAMA Dermatology|April 14, 2021
Association Between Systemic Corticosteroid Treatment for Cutaneous Immune-Related Adverse Events and Survival Outcomes in Patients With Advanced CancerLeah L Thompson, Jaewon Yoon, Nira A Krasnow, et al.
Journal of the American Academy of Dermatology|July 2, 2022
Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoidJordan T Said, Jordan Talia, Erin Wei, et al.
Journal of the American Academy of Dermatology|August 20, 2025
Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetesNatalie Braun, Claire Lin, Natalie Baker, et al.
International Journal of Dermatology|March 18, 2026
Effect of Diuretics on Cutaneous Squamous Cell Carcinoma: Clinical and Translational EvidenceKevin Sheng-Kai Ma, Stefano Sol, Fabiana Boncimino, et al.
Journal for Immunotherapy of Cancer|November 9, 2019
Budesonide treatment for microscopic colitis from immune checkpoint inhibitorsMichael S Hughes, Gabriel E Molina, Steven T Chen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 24, 2026
Effect of pre-existing atopic dermatitis on clinical outcomes of immune checkpoint therapyNatalie Braun, Bryan L Peacker, Natalie Baker, et al.
The British Journal of Dermatology|May 29, 2024
Sodium-glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseasesChin-Hsuan Shen, Yi-Sun Yang, Irene Tai-Lin Lee, et al.
International Journal of Dermatology|November 26, 2024
External validation study of Re-SCORTEN in patients with Stevens-Johnson syndrome and toxic epidermal necrolysisMike Westmeijer, Joseph Ebriani, Beatrix B Thompson, et al.
The American Journal of Dermatopathology|December 10, 2021
Cutaneous Findings of Sporadic, Adult-Onset Neuronal Intranuclear Inclusion DiseaseJakob M T Moran, Katharina Eikermann-Haerter, Otto Rapalino, et al.
Pageof 16